Introduction With the advent and availability of targeted therapy, the treatment of
advanced/metastatic renal cell carcinoma (RCC) underwent a drastic change in 2005. The …

Background The aims of this study were to investigate prognosis and validate prognostic
models [Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic Renal …

Purpose: We assessed temporal shifts in the frequency of risk factors for patients with
metastatic renal cell carcinoma in a multicenter, international data set. Materials and …

Aim: This retrospective study evaluates whether metastatic sites were associated with
progression-free survival (PFS) and overall survival (OS) in patients with renal cell …

Targeted therapy has changed the treatment of metastatic renal cell carcinoma (mRCC).
However, it is unclear if patients need to start systemic therapy immediately or if treatment …

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among
the highest in the world. Several targeted agents have been recently approved for the …

Introduction Metastasectomy (MSX) is considered a treatment option in patients with
metastatic renal cell carcinoma (mRCC) at diagnosis, but its role in the targeted therapy era …

Abstract Introduction/Background Targeted therapy has become the mainstay of treatment
for mRCC. The efficacy of this therapy in the older population is poorly understood. Patients …

Global survival studies have shown favorable development in renal cell carcinoma (RCC)
treatment but few studies have considered extended periods or covered populations for …

4536 Background: Clinical trials have strict eligibility criteria that exclude many patients to
whom the trial results are later extrapolated to in clinical practice. Methods: mRCC patients …